For example, in the ICC 2022 classification, MDS-RS has been replaced by an entity called MDS with mutated SF3B1. Likewise, the new schema differentiates MDS with mutated TP53 (0–9 percent blasts) from MDS/AML (with mutated p53 and 10–19 percent blasts), because the presence of multi-hit TP53 mutations in cytopenic myeloid neoplasms corresponds to a highly aggressive disease with a short survival period, regardless of morphologic features including blast count [12]. This evidence concerns the gene TP53 and myelodysplastic syndrome.